On February 7, 2022 Kyowa Hakko Kirin reported that Consolidated Financial Summary (IFRS)Fiscal 2021 (Press release, Kyowa Hakko Kirin, FEB 7, 2022, View Source [SID1234607779])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (from January 1, 2021 to December 31, 2021)

(1) Consolidated operating results
(2) Consolidated financial position
(3) Consolidated cash flows

2. Dividends

3. Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2022 (from January 1, 2022 to December 31, 2022) Non-Consolidated Results for the Fiscal Year Ended December 31, 2021 (Japanese GAAP) (from January 1, 2021 to December 31, 2021)
(1) Non-consolidated operating results
(2) Non-consolidated financial position

These financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.

* Notice regarding the appropriate use of the earnings forecasts and other special comments
The forward-looking statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.

For more information regarding our suppositions that form the assumptions for the earnings forecasts, please see pages 17 and 18 of the attachment, "(5) Outlook for Fiscal 2022" in "
1. Summary of Business Performance and Financial Position."

On February 7, 2022 Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, "Kyowa Kirin", TSE: 4151) reported that it will make changes to its organization as of April 1, 2022 (Press release, Kyowa Hakko Kirin, FEB 7, 2022, View Source [SID1234607780]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Outline of the changes:
1) The Strategy Division will be newly established.
2) The Corporate Strategy & Planning Department will be split into the Corporate Strategy Department and the Corporate Planning Department, and both departments will be placed in the Strategy Division.
3) The name of the Overseas Business Planning Department will be changed to the Overseas Business Strategy Department, which will be placed in the Strategy Division.
4) The Established Medicine Strategy Department will be newly established and placed in the Strategy Division.

Purpose of the organization changes:
1) Given the development of the business of Kyowa Kirin including its globalization, in addition to consolidating and coordinating each business and product strategy department, to establish a structure to supervise non-financial topics and established medicines as well.
2) To systematically position the functions of supervising its mid-and long-term corporate strategy and managing its corporate plan.
3) To strengthen overseas business strategies and strategic management of regional headquarters.
4) To develop and execute product strategies closely coordinated with business management.
5) To comprehensively grasp the status of established medicines that Kyowa Kirin owns and to supervise business execution to ensure that it proceeds efficiently.

On February 7, 2022 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported that the Company will participate in the 2022 BIO CEO & Investor Conference on February 14-17, 2022 (Press release, Cyclacel, FEB 7, 2022, View Source [SID1234607797]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference details can be found below:

BIO CEO & Investor Conference: virtual meetings and on-demand presentation (available on conference site February 11, 2022)
Date: 1-on-1 virtual meetings with senior management February 14-17, 2022
Registration Link
The presentation can be accessed for 90 days and can be found on the Cyclacel website at www.cyclacel.com.

On February 7, 2022 aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, reported that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference, which is being held February 14 – 17, 2022, at the Marriott Marquis in New York, NY (Press release, aTyr Pharma, FEB 7, 2022, View Source [SID1234607798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Shukla will present on Tuesday, February 15, 2022, at 1:15 p.m. EST.

Company management will also participate in in-person and virtual one-on-one meetings during the conference. Meetings can be scheduled through the conference partnering system or by contacting [email protected].

On February 7, 2022 Nordic Pharma reported that they have entered into an agreement with SANOFI to fully acquire the rights to ALTIM (cortivazol), a legacy product in France (Press release, Nordic Pharma, FEB 7, 2022, View Source [SID1234607876]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALTIM contains a 3.75mg/1.5ml cortivazol suspension for injection, presented in a pre-filled syringe, and is approved in France in Rheumatology indications, where a local corticosteroid treatment is required.
See prescribing information: Résumé des caractéristiques du produit – ALTIM 3,75 mg/1,5 ml, suspension injectable en seringue pré-remplie – Base de données publique des médicaments (medicaments.gouv.fr)

This acquisition supports Nordic Pharma’s strategy to grow its proprietary portfolio and to become a key player in Rheumatology in France and beyond.

ALTIM was commercialized in France since the 70’s and subsequently withdrawn from the French market by Sanofi in 2018 due to manufacturing issues. It is the intention of Nordic Pharma to re-engineer the process and the manufacturing for both the active substance and the finished product to allow the product to be re-launched onto the French market at the earliest possibility as the product is still requested by clinicians.

Jean-Michel Quinot, CEO of Nordic Pharma stated:" We are very pleased to have reached an agreement with Sanofi allowing us to re-introduce ALTIM into the French market. Nordic Pharma is dedicated to providing Patients and Physicians with innovative medications addressing significant unmet medical needs. We are very eager to further expand our successful collaboration with Sanofi."

Veronique Rebours-Mory, CSO of Nordic Pharma stated: "Physicians are still demanding this unique treatment option for Rheumatology patients, and despite the challenge and investment needed, we are committed to solving the manufacturing issues that led to the discontinuation of the product."